Скачать или смотреть Cladribine vs S1P Modulators: New Study Shows Better Disability Protection in Treatment-Naive RRMS

A groundbreaking comparative study reveals that cladribine offers superior protection against disability progression compared to sphingosine-1-phosphate receptor modulators (S1PRMs) in treatment-naive relapsing-remitting multiple sclerosis (RRMS). This video breaks down the key findings, including relapse rates, MRI outcomes, and long-term implications for patients. Learn why early treatment choice matters and how cladribine could be a game-changer for newly diagnosed RRMS patients, especially younger individuals with lower baseline disability. Stay informed about the latest advancements in MS treatment and what they mean for patient care.
Key Topics Covered:
Cladribine vs S1PRMs in RRMS
Disability progression and relapse rates
Real-world study data from Italian MS centers
Long-term treatment considerations
Clinical implications for clinicians and patients
Don’t forget to like, share, and subscribe for more updates on multiple sclerosis research and treatment options!